慢性肠系膜缺血的开放与腔内血运重建的成本效果分析
本研究采用马尔可夫模型与蒙特卡洛微观模拟,基于现有文献的转移概率和效用值,比较开放血运重建(OR)与腔内血运重建(ER)治疗慢性肠系膜缺血(CMI)的成本效果。模型随机分配20,000例患者,分析5年质量调整生命年(QALYs)、成本和增量成本效果比(ICER)。结果显示OR成本4,532美元获得1.03 QALYs,ER成本5,092美元获得1.21 QALYs,ICER为每获得1个QALY 3,037美元,低于支付意愿阈值100,000美元,概率敏感性分析显示ER在99%的迭代中被认为具有成本效果。
要点
- ER治疗CMI的5年成本高于OR,但获得的QALYs更多。
- ER的ICER为每QALY 3,037美元,低于100,000美元支付意愿阈值。
- 概率敏感性分析显示ER在99%的迭代中具有成本效果。
核心结论
- 虽然ER的5年成本高于OR,但ER提供的QALYs多于OR,且ER治疗CMI似乎比OR更具成本效果。
研究设计与样本
- 马尔可夫模型与蒙特卡洛微观模拟,使用现有文献中CMI患者接受OR或ER的转移概率和效用值,成本基于2020年Medicare医师费用表从医院角度得出,模型随机分配20,000例患者至OR或ER,允许1次后续再干预,分析5年内的QALYs、成本和ICER,并进行单因素敏感性和概率敏感性分析。
主要发现
- OR成本4,532美元获得1.03 QALYs,ER成本5,092美元获得1.21 QALYs,ER组的ICER为每获得1个QALY 3,037美元。
- 该ICER低于支付意愿阈值100,000美元。
- 敏感性分析显示模型对OR和ER后的成本、死亡率和通畅率最为敏感。
- 概率敏感性分析显示ER在99%的迭代中被认为具有成本效果。
关键数值与推荐
- OR成本4,532美元获得1.03 QALYs。
- ER成本5,092美元获得1.21 QALYs。
- ER组ICER为每获得1个QALY 3,037美元。
- 支付意愿阈值为100,000美元。
- 概率敏感性分析中ER在99%的迭代中被认为具有成本效果。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recent studies have shown a trend supporting endovascular revascularization (ER) in the treatment of chronic mesenteric ischemia (CMI). However, few studies have compared the cost effectiveness of ER and open revascularization (OR) for this indication. The purpose of this study is to conduct a cost-effectiveness analysis comparing open versus ER for CMI. METHODS: We built a Markov model with Monte Carlo microsimulation using transition probabilities and utilities from existing literature for CMI patients undergoing OR versus ER. Costs were derived from the hospital perspective using the 2020 Medicare Physician Fee Schedule. The model randomized 20,000 patients to either OR or ER and allowed for 1 subsequent reintervention with 3 other intervening health states: alive, alive with complications, and dead. Quality-adjusted life years (QALYs), costs, and incremental cost-effectiveness ratio (ICER) were analyzed over a 5-year period. One-way sensitivity and probabilistic sensitivity analyses were conducted to study the impact of parameter variability on cost effectiveness. RESULTS: OR cost $4,532 for 1.03 QALYs while ER cost $5,092 for 1.21 QALYs, leading to an ICER of $3,037 per QALY gained in the ER arm. This ICER was less than our willingness to pay threshold of $100,000. Sensitivity analysis demonstrated that our model was most sensitive to costs, mortality, and patency rates after OR and ER. Probabilistic sensitivity analysis demonstrated ER would be considered cost effective 99% of iterations. CONCLUSIONS: This study found that while 5-year costs for ER were greater than OR, ER afforded greater QALYs than OR. Although ER is associated with lower long-term patency and higher rates of reintervention, it appears to be more cost effective than OR for the treatment of CMI.
引用
- Patel RJ, Cui C, Khan MA, et al. Cost-Effectiveness Analysis of Open Versus Endovascular Revascularization for Chronic Mesenteric Ischemia. Ann Vasc Surg. 2023. PMID: 36878356. doi:10.1016/j.avsg.2023.02.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。